Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions

Lymphoma, B-CellT-Cell Lymphoma

Interventions

DRUG

RP6530

Escalating doses starting at 25 mg BID

Trial Locations (3)

Rhizen Trial Site, Paris

Rhizen Trial Site 1, Milan

Rhizen Trial Site 2, Milan

All Listed Sponsors

lead

Rhizen Pharmaceuticals SA

INDUSTRY

NCT02017613 - Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies | Biotech Hunter | Biotech Hunter